2016年北美囊性纤维化会议亮点
Highlights from the 2016 North American Cystic Fibrosis Conference.
作者信息
Zemanick Edith T, Daines Cori L, Dellon Elisabeth P, Esther Charles R, Kinghorn BreAnna, Ong Thida, Muhlebach Marianne S
机构信息
Department of Pediatrics, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado.
Department of Pediatrics, University of Arizona College of Medicine, Tucson, Arizona.
出版信息
Pediatr Pulmonol. 2017 Aug;52(8):1103-1110. doi: 10.1002/ppul.23707. Epub 2017 Jul 11.
Abstract
The 30th annual North American Cystic Fibrosis Conference (NACFC) was held in Orlando, FL, on October 27-29, 2016. Abstracts were published in a supplement to Pediatric Pulmonology. This review summarizes several major topic areas addressed at the conference: the pathophysiology of cystic fibrosis (CF) lung disease, clinical trials, clinical management issues, and quality improvement. We sought to provide an overview of emerging concepts in several areas of CF research and care, rather than a comprehensive review of the conference. Citations from the conference are by first author and abstract number or symposium number, as designated in the supplement.
摘要
第30届北美囊性纤维化会议（NACFC）于2016年10月27日至29日在佛罗里达州奥兰多市举行。会议摘要发表在《儿科肺病学》增刊上。本综述总结了会议涉及的几个主要主题领域：囊性纤维化（CF）肺病的病理生理学、临床试验、临床管理问题以及质量改进。我们旨在概述CF研究和护理几个领域的新出现概念，而非对会议进行全面综述。会议引用内容按增刊中指定的第一作者及摘要编号或研讨会编号列出。
相似文献
1
Highlights from the 2016 North American Cystic Fibrosis Conference.2016年北美囊性纤维化会议亮点
Pediatr Pulmonol. 2017 Aug;52(8):1103-1110. doi: 10.1002/ppul.23707. Epub 2017 Jul 11.
2
Highlights from the 2017 North American Cystic Fibrosis Conference.2017 年北美囊性纤维化会议亮点。
Pediatr Pulmonol. 2018 Jul;53(7):979-986. doi: 10.1002/ppul.24000. Epub 2018 Apr 16.
3
Highlights from the 2015 North American Cystic Fibrosis Conference.2015年北美囊性纤维化会议亮点。
Pediatr Pulmonol. 2016 Jun;51(6):650-7. doi: 10.1002/ppul.23441. Epub 2016 Apr 13.
4
Highlights from the 2019 North American Cystic Fibrosis Conference.2019 年北美囊性纤维化会议亮点。
Pediatr Pulmonol. 2020 Sep;55(9):2225-2232. doi: 10.1002/ppul.24919. Epub 2020 Jul 3.
5
Highlights from the 2018 North American cystic fibrosis conference.2018 年北美囊性纤维化会议亮点。
Pediatr Pulmonol. 2019 Jul;54(7):941-948. doi: 10.1002/ppul.24356. Epub 2019 May 15.
6
Highlights from the 30th North American Cystic Fibrosis Conference, Orlando 2016.第 30 届北美囊性纤维化会议亮点，奥兰多 2016 年。
Paediatr Respir Rev. 2018 Mar;26:1-3. doi: 10.1016/j.prrv.2017.03.010. Epub 2017 Mar 14.
7
Highlights of the North American CF Conference 2013.2013 年北美 CF 会议要点。
Paediatr Respir Rev. 2014 Jun;15 Suppl 1:8-9. doi: 10.1016/j.prrv.2014.04.005. Epub 2014 Apr 13.
8
Highlights of the 28(th) North American Cystic Fibrosis Conference 2014.2014年第28届北美囊性纤维化会议亮点
Paediatr Respir Rev. 2015 Oct;16 Suppl 1:12-4. doi: 10.1016/j.prrv.2015.07.009. Epub 2015 Sep 26.
9
10
Healthcare improvement is incomplete until it is published: the cystic fibrosis initiative to support scholarly publication.医疗保健的改善直到发表才完整：支持学术出版的囊性纤维化倡议。
BMJ Qual Saf. 2014 Apr;23 Suppl 1:i104-7. doi: 10.1136/bmjqs-2014-002844.
引用本文的文献
1
Sustained Reduction in Time to Data Entry in the Cystic Fibrosis Foundation Registry.囊性纤维化基金会登记处数据录入时间的持续缩短。
Pediatr Qual Saf. 2022 Jan 21;7(1):e529. doi: 10.1097/pq9.0000000000000529. eCollection 2022 Jan-Feb.
2
Nutritional status and muscle dysfunction in chronic respiratory diseases: stable phase versus acute exacerbations.慢性呼吸道疾病中的营养状况与肌肉功能障碍：稳定期与急性加重期对比
J Thorac Dis. 2018 May;10(Suppl 12):S1332-S1354. doi: 10.21037/jtd.2018.02.66.
3
Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients.泰利万星对包括耐头孢洛林降低的金黄色葡萄球菌分离株在内的囊性纤维化患者分离株的活性。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00956-18. Print 2018 Sep.
本文引用的文献
1
OPTN/SRTR 2015 Annual Data Report: Lung.器官获取与移植网络/器官共享联合网络2015年度数据报告：肺脏
Am J Transplant. 2017 Jan;17 Suppl 1:357-424. doi: 10.1111/ajt.14129.
2
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.评估长期使用组合 Lumacaftor 和 Ivacaftor 疗法治疗囊性纤维化纯合子 F508del-CFTR 突变患者的安全性和疗效（PROGRESS）：一项 3 期扩展研究。
Lancet Respir Med. 2017 Feb;5(2):107-118. doi: 10.1016/S2213-2600(16)30427-1. Epub 2016 Dec 21.
3
Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR.鲁马卡托/依伐卡托用于6至11岁患有囊性纤维化且F508del-CFTR基因纯合的患者。
Am J Respir Crit Care Med. 2017 Apr 1;195(7):912-920. doi: 10.1164/rccm.201608-1754OC.
4
CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis.CFTR调节剂：为囊性纤维化的精准医学带来曙光。
Front Pharmacol. 2016 Sep 5;7:275. doi: 10.3389/fphar.2016.00275. eCollection 2016.
5
An Official American Thoracic Society Workshop Report 2015. Stem Cells and Cell Therapies in Lung Biology and Diseases.2015年美国胸科学会官方研讨会报告。肺生物学与疾病中的干细胞和细胞疗法。
Ann Am Thorac Soc. 2016 Aug;13(8):S259-78. doi: 10.1513/AnnalsATS.201606-466ST.
6
Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.发现可促进抑制囊性纤维化跨膜传导调节因子无义突变的临床批准药物。
Am J Respir Crit Care Med. 2016 Nov 1;194(9):1092-1103. doi: 10.1164/rccm.201601-0154OC.
7
Highlights from the 2015 North American Cystic Fibrosis Conference.2015年北美囊性纤维化会议亮点。
Pediatr Pulmonol. 2016 Jun;51(6):650-7. doi: 10.1002/ppul.23441. Epub 2016 Apr 13.
8
Cystic fibrosis: a model system for precision medicine.囊性纤维化：精准医学的模型系统。
Curr Opin Pediatr. 2016 Jun;28(3):312-7. doi: 10.1097/MOP.0000000000000351.
9
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.一项 3 期、多中心、跨国、随机、双盲、安慰剂对照研究，旨在评估左氧氟沙星吸入溶液（APT-1026）在稳定期囊性纤维化患者中的疗效和安全性。
J Cyst Fibros. 2016 Jul;15(4):495-502. doi: 10.1016/j.jcf.2015.12.004. Epub 2016 Feb 4.
10
Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.在囊性纤维化和 CFTR 门控突变（KIWI）的 2-5 岁患者中，ivacaftor 的安全性、药代动力学和药效学：一项开放标签、单臂研究。
Lancet Respir Med. 2016 Feb;4(2):107-15. doi: 10.1016/S2213-2600(15)00545-7. Epub 2016 Jan 21.
Zotero 插件